Adamis Prostate Cancer Drug APC-100 Receives Allowance for Patent in Canada Adamis Pharmaceuticals Corporation, announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in Canada. Broad claims to a patent entitled “Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders” have been allowed. [BusinessWire] Press Release